-
International Journal of Women's Health
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Clinical trials and progress with paclitaxel in ovarian cancer
Review
(2400) Views (689) Full article downloads
Authors: Sanjeev Kumar, Haider Mahdi, Christopher Bryant, et al
Published Date November 2010
Volume 2010:2 Pages 411 - 427
DOI: http://dx.doi.org/10.2147/IJWH.S7012
Sanjeev Kumar1, Haider Mahdi2, Christopher Bryant1, Jay P Shah1, Gunjal Garg3, Adnan Munkarah41Department of Obstetrics and Gynecology, Wayne State University School of Medicine and Karmanos Cancer Institute Detroit, Michigan; 2Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington; 3Department of Obstetrics and Gynecology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; 4Department of Obstetrics and Gynecology, Henry Ford Hospital, Detroit, Michigan, USA
Abstract: Paclitaxel is a front-line agent for ovarian cancer chemotherapy, along with the platinum agents. Derived from the Pacific yew tree, Taxus brevifolia, paclitaxel has covered significant ground from the initial discovery of its antineoplastic properties to clinical applications in many forms of human cancers, including ovarian cancer. Although much has been published about the unique mechanism of action of this agent, several issues remain to be resolved. Finding the appropriate dosage schedule for paclitaxel in chemo-naïve and recurrent ovarian cancer, defining the role of paclitaxel in maintenance chemotherapy, and elucidating the mechanisms of taxane resistance are areas of intense research. Newer forms of taxanes are being manufactured to avoid troublesome adverse effects and to improve clinical efficacy. These issues are reviewed in detail in this paper with an emphasis on clinically relevant evidence-based information.
Keywords: paclitaxel, clinical trials, ovarian cancer, treatment
Readers of this article also read:
Erratum
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Diagnosis and management of pre-eclampsia: an update
Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis
A case of recurrent bloody tears
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Enhanced transdermal delivery of evodiamine and rutaecarpine using microemulsion
- Interested in being a peer-reviewer?
Click here to register.
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Contraceptive practices in Nigeria: Literature review and recommendation for future policy decisions
- Tinidazole in the treatment of bacterial vaginosis
- Diagnosis and management of pre-eclampsia: an update
- Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy




